Go to the list of all blogs
M. Benett's Avatar
published in Blogs
Nov 16, 2026
TickeronGET DAILY SIGNALS
Why Is Bullfrog AI Holdings (BFRG) Stock Down -7.55% Today?

Why Is Bullfrog AI Holdings (BFRG) Stock Down -7.55% Today?

Key Takeaways

  • Bullfrog AI Holdings (BFRG) shares fell 7.55% to $0.49 in late-morning trading Monday, extending the post-earnings decline from Friday's $0.53 close.
  • The primary catalyst is the third-quarter report: collaboration revenue of $63,578 came in roughly 70% below the $215,000 consensus and fell 24% year over year, while the operating loss widened to $2.05 million.
  • A secondary driver is the accompanying 10-Q disclosure that shares outstanding rose to 18.69 million from 11.42 million at the end of 2025 — a fresh reminder of dilution that keeps per-share economics under pressure.
  • Broader tape: a firmly risk-off session with the Nasdaq-100 proxy QQQ down 1.96%, IWM off 0.94% and biotech gauge XBI down 1.35%, amplifying selling in high-beta micro-caps.
  • Volume is running ahead of the recent pace, with more than 50,000 shares changing hands in the first hour against a nine-session daily average near 115,000.
  • News Significance Score: 28/100 — a sharp revenue miss paired with a price move only modestly larger than this stock's typical swing.
  • Traders are watching whether the top-five pharmaceutical client expands beyond one program, the $4.99 million cash position against a roughly $2 million quarterly burn, and the path back toward the $1 bid price.
  • For deeper detail on Price Targets, Earnings and Forecast data, explore Tickeron's dedicated pages for this symbol.
  • Investors hunting for systematic strategies can browse Trending AI Robots to see which automated strategies are performing best right now.

Bullfrog AI Stock Slides in Monday Trading

Bullfrog AI Holdings, Inc. (BFRG) is a Gaithersburg, Maryland-based digital biopharmaceutical company that sells an artificial intelligence and machine learning analytics platform, bfLEAP, to drug developers, and also advances its own early-stage candidates in glioblastoma and metabolic disease. Shares were quoted at $0.49 on Monday morning, down 7.55% from the prior close of $0.53, putting the micro-cap on track for its second straight down session. The move lower follows Friday's third-quarter release and a post-earnings conference call held after that day's closing bell, which left Monday as the first full session in which investors could react to management's commentary alongside the 10-Q.

Q3 Revenue Miss Resets Expectations

The revenue line is the crux of the selling. Bullfrog AI booked $63,578 of collaboration revenue in the quarter ended September 30, against $83,413 a year earlier and a consensus estimate near $215,000 — a shortfall of roughly 70%. That follows a much stronger second quarter, when the company recognized $215,385 after completing the first deliverable under its agreement with a top-five global pharmaceutical partner covering major depressive disorder.

The swing highlights the lumpiness of a milestone-based model with a single anchor client. Operating expenses rose to $2.06 million from $1.66 million, producing an operating loss of $2.05 million versus $1.57 million. The reported per-share loss of $0.11 also came in wider than the $0.09 consensus, though it improved from $0.15 a year earlier. For a company with a market value near $9 million, a quarterly revenue figure in the tens of thousands is a material signal about how slowly commercialization is scaling.

Dilution and Balance Sheet Optics

The 10-Q added a second layer of pressure. Common shares outstanding stood at 18.69 million as of November 12, up from 11.42 million at December 31, 2025 — growth of roughly 64% in under a year, driven by equity raises used to fund operations and satisfy listing requirements. Cash and equivalents rose to $4.99 million from $2.18 million over the same period, so the balance sheet is stronger, but each dollar of that improvement came at the cost of a larger share count. With first-half losses running near $3 million and additional equity capacity in place, investors are weighing the runway against further issuance risk.

Broader Market Weakness Amplifies the Move

Bullfrog AI did not fall in a vacuum. Monday's session was broadly risk-off, with the Nasdaq-100 proxy QQQ down 1.96%, the S&P 500 proxy SPY off 1.14%, small caps as measured by IWM down 0.94% and the biotech benchmark XBI lower by 1.35%. Pre-revenue and early-revenue names with high beta typically underperform on days like this, and the company-specific disappointment compounded the drag. The decline is therefore best read as company news plus macro beta rather than a sector-specific event.

Market Context and Trading Activity

Turnover has picked up meaningfully. More than 50,000 shares traded in the first hour of Monday's session, against an average of roughly 115,000 a day over the prior nine sessions — a pace consistent with a full day above recent norms. The stock gapped lower at the open near $0.50 and has traded in a $0.48 to $0.52 band, briefly printing a $0.48 low. That puts shares beneath both the 50-day moving average around $0.55 and the 200-day average near $0.64, and roughly 13% above the 52-week low of $0.425. Momentum has faded since the September spike that briefly carried the stock above $1.00 on insider buying and the depression-target data.

News Significance Score

The score runs from 0 — no meaningful news and a move typical for the stock — to 100, meaning transformative news plus an extreme, rare price move. Bullfrog AI lands at 28 out of 100.

The verified news is genuine but small in absolute terms: a quarterly revenue line that missed by roughly 70%, a wider operating loss, and a share count up 64% year to date. The price move, however, is only about 1.4 times the stock's average absolute daily change of roughly 5.5% over the past 60 sessions, and moves of this size or larger occurred eight times in that window. Weak-to-moderate news combined with an unremarkable move for this name produces a low-to-mid score.

What Comes Next for BFRG

Attention now shifts to the fourth quarter, where the single analyst covering the name looks for a loss of about $0.10 a share on roughly $350,000 of revenue. The central question is whether the top-five pharmaceutical partner converts the completed depression-target work into a second paid program, and whether any new clients sign. Investors will also track cash consumption against the $4.99 million balance, any use of the remaining equity line, and the stock's distance from the $1 minimum bid threshold that triggered a Nasdaq notice earlier this year. Sector sentiment toward small-cap AI drug-discovery names remains a swing factor, and the shares carry elevated risk given thin liquidity, a concentrated client base and continued funding needs.

Trending AI Robots

Tickeron maintains hundreds of AI trading bots covering thousands of tickers, but only the strongest performers under current market conditions are surfaced in its curated Trending AI Robots section. The bots differ widely by strategy, timeframe, performance metrics and the symbols they trade, so the lineup rotates as market conditions shift. For traders looking to pair discretionary ideas with systematic execution, reviewing the current leaders is a practical next step.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: BFRG

BFRG saw its Stochastic Oscillator peaks and leaves the overbought zone

The Stochastic Oscillator for BFRG moved out of overbought territory on November 13, 2026. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 26 similar instances where the indicator exited the overbought zone. In 25 of the 26 cases the stock moved lower. This puts the odds of a downward move at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BFRG as a result. In 76 of 80 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.

BFRG moved below its 50-day moving average on November 12, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for BFRG crossed bearishly below the 50-day moving average on October 21, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BFRG declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

BFRG broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for BFRG entered a downward trend on November 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for BFRG just turned positive on November 04, 2026. Looking at past instances where BFRG's MACD turned positive, the stock continued to rise in 31 of 33 cases over the following month. The odds of a continued upward trend are 90%.

Following a +15.62% 3-day Advance, the price is estimated to grow further. Considering data from situations where BFRG advanced for three days, in 118 of 148 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 23 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 59 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.375) is normal, around the industry mean (4.523). P/E Ratio (-1.126) is within average values for comparable stocks, (12.601). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.536). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. BFRG's P/S Ratio (19.268) is slightly higher than the industry average of (6.105).

The Tickeron Price Growth Rating for this company is 61 (best 1 - 100 worst), indicating fairly steady price growth. BFRG’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BFRG’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 97, placing this stock worse than average.

Notable companies

The most notable companies in this group are Teladoc Health (NYSE:TDOC).

Industry description

This industry comprises companies that provide services, such as equipment sterilization, research, physician management systems and consulting, that support the healthcare/medical industry. Examples of such companies include Laboratory Corporation of America Holdings, which operates one of the largest clinical laboratory networks in the world; Quest Diagnostics Inc., which is a clinical laboratory; and Syneos Health, which is a major clinical research organization.

Market Cap

The average market capitalization across the Services to the Health Industry Industry is 3.31B. The market cap for tickers in the group ranges from 708 to 49.18B. VEEV holds the highest valuation in this group at 49.18B. The lowest valued company is OTRKQ at 708.

High and low price notable news

The average weekly price growth across all stocks in the Services to the Health Industry Industry was -7%. For the same Industry, the average monthly price growth was 0%, and the average quarterly price growth was 14%. DH experienced the highest price growth at 12%, while DRIO experienced the biggest fall at -44%.

Volume

The average weekly volume growth across all stocks in the Services to the Health Industry Industry was -24%. For the same stocks of the Industry, the average monthly volume growth was -12% and the average quarterly volume growth was -35%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 52
Price Growth Rating: 53
SMR Rating: 86
Profit Risk Rating: 96
Seasonality Score: 2 (-100 ... +100)
1-on-1 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry ServicestotheHealthIndustry

Industry
N/A
Address
325 Ellington Boulevard
Phone
+1 240 658-6710
Employees
17
Web
https://www.bullfrogai.com
Interact to see
Advertisement
Different growth engines: MRVL is riding accelerating AI data-center demand for custom chips and networking, while QCOM remains heavily tied to a soft smartphone market. Momentum contrast: Marvell's data-center revenue guidance has strengthened, whereas Qualcomm's near-term outlook has been pressured by memory-supply constraints and shrinking handset volumes.
SAP's U.S. shares fell from Monday's close of $233.83 to $221.99 by late Tuesday morning in New York, a -5.06% decline recorded during regular trading hours. The company-specific trigger was the announced exit of Chief Customer Officer Thomas Saueressig, an executive board member since 2019, who will leave at the end of March 2027 to become CEO of IONOS; the disclosure came before the U.S. open.
TMC fell from Monday's $2.11 close to $1.96 by 10:10 a.m. ET, a -7.11% decline that occurred entirely in the regular session after an early premarket gain faded. No verified news or fundamental catalyst found for the drop; the move is likely technical, extending the post-Q3 unwind that followed NOAA pushing its certification decision to mid-December, with the stock averaging a 4.0% daily swing and logging 11 sessions of 7%-or-larger moves in the last 60.
IonQ slid from Monday's close of $26.45 to $24.73 on Tuesday, a -6.50% move that unfolded during regular trading hours after modest premarket gains faded. The decline was sector-driven rather than company-specific: quantum and AI-adjacent speculative names extended a multi-session liquidation ahead of Nvidia's quarterly report, with unease over Nvidia's abrupt CEO transition keeping risk appetite weak.
SKHY fell -6.87% to $122.74 by 10:04 a.m. ET, down $9.05 from Friday's close of $131.79, extending a premarket decline into the regular session. The drop was driven by a sector-wide AI chip selloff ahead of Nvidia's quarterly results on Tuesday, where CEO Jensen Huang's resignation has raised doubts about the durability of data-center spending that underpins high-bandwidth memory demand.